比较不同新辅助化疗方案联合或不联合立体定向体部放疗治疗交界可切除胰腺癌:前瞻性随机II期试验(BRPCNCC-1)研究方案
该研究为前瞻性随机II期试验,纳入活检及影像学确诊的交界可切除胰腺癌患者,随机分为三组:吉西他滨联合白蛋白结合型紫杉醇、该方案联合SBRT、S-1联合白蛋白结合型紫杉醇联合SBRT。主要终点为总生存期,旨在探讨新辅助化疗联合SBRT是否优于单纯化疗,并比较含吉西他滨与含S-1方案联合SBRT的疗效。
要点
- 研究比较新辅助化疗联合或不联合SBRT治疗交界可切除胰腺癌的疗效。
- SBRT剂量为7.5-8Gy/次,共5次,SBRT后3周行手术切除。
- 主要终点为总生存期,次要终点包括无病生存期、病理完全缓解率、R0切除率和不良事件发生率。
核心结论
- 若结果显示新辅助化疗联合SBRT的生存获益以及S-1与吉西他滨方案结局相似,可能为该模式用于交界可切除胰腺癌的临床实践提供证据。
研究设计与样本
- 前瞻性随机II期试验,纳入活检及影像学确诊的交界可切除胰腺癌、无既往治疗及严重合并症的患者,随机分配至三组。
主要发现
- 三组分别为新辅助吉西他滨联合白蛋白结合型紫杉醇、新辅助吉西他滨联合白蛋白结合型紫杉醇联合SBRT、新辅助S-1联合白蛋白结合型紫杉醇联合SBRT。
- SBRT放射剂量为7.5-8Gy/次,共5次;SBRT后3周行手术切除。
- 胰头肿瘤采用动脉优先入路胰十二指肠切除术,胰体尾肿瘤采用根治性顺行模块化胰脾切除术。
- 主要终点为总生存期;次要终点为无病生存期、病理完全缓解率、R0切除率和不良事件发生率。
关键数值与推荐
- 吉西他滨和白蛋白结合型紫杉醇使用标准剂量。
- SBRT剂量为7.5-8Gy/次,共5次。
- SBRT后3周行手术切除。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few patients with pancreatic cancer may be candidates for immediate surgical resection at the initial diagnosis. Even if patients with borderline resectable pancreatic cancer (BRPC), micrometastases may occur before surgery. Therefore, neoadjuvant therapy is vital for improved survival, which has been confirmed in previous studies that neoadjuvant chemotherapy with or without radiotherapy provides superior overall compared with upfront surgery. However, question of whether the addition of radiotherapy to neoadjuvant chemotherapy can improve prognosis compared with chemotherapy alone is a challenging matter. Moreover, most of previous studies only adopted conventional radiotherapy as the neoadjuvant modality though stereotactic body radiation therapy (SBRT) has been proven effective and commonly employed in pancreatic cancer. Also, no studies have evaluated the efficacy of S-1 as the neoadjuvant chemotherapy regimen for BRPC albeit similar prognosis has been found between S-1 and gemcitabine in advanced pancreatic cancer. Hence, the aim of this study is to investigate whether neoadjuvant chemotherapy plus SBRT results in better outcomes compared with neoadjuvant chemotherapy alone and also compare the efficacy of gemcitabine plus nab-paclitaxel with SBRT and S-1 plus nab-paclitaxel with SBRT. METHODS: Patients with biopsy and radiographically confirmed BRPC, no prior treatment and severe morbidities are enrolled. They will be randomly allocated into three groups: neoadjuvant gemcitabine plus nab-paclitaxel, neoadjuvant gemcitabine plus nab-paclitaxel with SBRT and neoadjuvant S-1 plus nab-paclitaxel with SBRT. Standard doses of gemcitabine and nab-paclitaxel are used. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT. Artery first approach pancreaticoduodenectomy or radical antegrade modular pancreatosplenectomy will be used for the tumor in the head or body and tail of the pancreas, respectively. The primary endpoint is overall survival. The secondary outcomes are disease free survival, pathological complete response rate, R0 resection rate and incidence of adverse effects. DISCUSSION: If results show the survival benefits of neoadjuvant chemotherapy plus SBRT and similar outcomes between S-1 and gemcitabine, it may provide evidence of clinical practice of this modality for BRPC. TRIAL REGISTRATION: The study has been registered in ClinicalTrial.gov ( NCT03777462 ).
引用
- Gao S, Zhu X, Shi X, et al. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). Radiat Oncol. 2019. PMID: 30917842. doi:10.1186/s13014-019-1254-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。